Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-91 Phase II Study in Biliary Tract Cancer
jRCT2080225006Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA) and 2 more, sponsored by Ono Pharmaceutical. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on jRCT2080225006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225006.